Overall, the results from this study suggest that slc7a8 might be a potential therapeutic target for controlling DIO, as well as for mitigating the development of some of the pathophysiological conditions associated with obesity. Here, SLC7A8 is linked to obesity due to melanocortin 4 receptor deficiency.